Whose Teva is it Anyway?
Insights - Teva Pharmaceuticals (TEVA) announced Wednesday that its CEO, Jeremy Levin, has stepped down after a tumultuous 18-month tenure. The question now is how long will … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Intermune’s Esbriet Sales Surprise on Upside
Insights - Intermune (ITMN) climbed 6% on Thursday morning after the company reported increased sales of their Idiopathic Pulmonary Fibrosis drug, Esbriet (pirfenidone). Q3 sales were $19.7 … Continue Reading
Read nowKaloBios Gets Orphan Designation for Cystic Fibrosis Drug
Insights - KaloBios (KBIO) got a boost Wednesday when the U.S. FDA granted orphan drug designation to its cystic fibrosis compound (KB001-A), which is currently in phase … Continue Reading
Read nowInvestigation into Questcor is Heating Up, Not Cooling Down
Most Popular - California-based Questcor Pharmaceuticals (QCOR) gave investors a case of whiplash Tuesday after reporting a fantastic quarter, yet following up with news about pending investigations into … Continue Reading
Read now
Here Are Some Details From Sunshine Heart’s Most Recent Presentation
Insights - On Tuesday at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, Sunshine Heart (SSH) presented updated results from the ongoing OPTIONS-HF European trial testing the … Continue Reading
Read nowVertex Third Quarter Results: Accepting the Inevitable and Moving Ahead
Long Ideas - The bad news finally came for Vertex Pharmaceuticals’ (VRTX) Hepatitis C drug, Incivek, and the company responded by cutting its workforce by 15%, or 370 … Continue Reading
Read nowZohydro’s Approval Was the First Step
Long Ideas - After a negative vote from the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and repeat signals that the regulatory agency was taking a hardline … Continue Reading
Read now